- Home
- SLRX vs ONCO Comparison
SLRX vs ONCO Comparison
Compare SLRX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- ONCO
- Stock Information
- Founded
- SLRX N/A
- ONCO 2018
- Country
- SLRX United States
- ONCO United States
- Employees
- SLRX N/A
- ONCO N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- ONCO Health Care
- Exchange
- SLRX Nasdaq
- ONCO Nasdaq
- Market Cap
- SLRX 1.8M
- ONCO 1.8M
- IPO Year
- SLRX N/A
- ONCO 2022
- Fundamental
- Price
- SLRX $0.72
- ONCO $0.07
- Analyst Decision
- SLRX
- ONCO
- Analyst Count
- SLRX 0
- ONCO 0
- Target Price
- SLRX N/A
- ONCO N/A
- AVG Volume (30 Days)
- SLRX 23.3K
- ONCO 44.3M
- Earning Date
- SLRX 05-14-2025
- ONCO 06-17-2025
- Dividend Yield
- SLRX N/A
- ONCO N/A
- EPS Growth
- SLRX N/A
- ONCO N/A
- EPS
- SLRX N/A
- ONCO N/A
- Revenue
- SLRX N/A
- ONCO $2,524,116.00
- Revenue This Year
- SLRX N/A
- ONCO N/A
- Revenue Next Year
- SLRX N/A
- ONCO N/A
- P/E Ratio
- SLRX N/A
- ONCO N/A
- Revenue Growth
- SLRX N/A
- ONCO 4217.31
- 52 Week Low
- SLRX $0.45
- ONCO $0.05
- 52 Week High
- SLRX $7.20
- ONCO $14.00
- Technical
- Relative Strength Index (RSI)
- SLRX 41.78
- ONCO 45.72
- Support Level
- SLRX $0.68
- ONCO $0.07
- Resistance Level
- SLRX $0.80
- ONCO $0.09
- Average True Range (ATR)
- SLRX 0.04
- ONCO 0.01
- MACD
- SLRX -0.01
- ONCO 0.00
- Stochastic Oscillator
- SLRX 8.93
- ONCO 25.67
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.